(HealthDay News) — Metformin use is associated with lower risks for dementia and all-cause mortality across body mass index (BMI) groups in patients with overweight or obesity, according to a study ...

(HealthDay News) — In 2024, 26.5 percent of adults with diagnosed diabetes used glucagon-like peptide 1 receptor agonist (GLP-1 RA) injectables, according to an August data brief published by the ...

There is decreased risk for MACE and all-cause mortality in dialysis-dependent patients with ASCVD who are treated with statins.

The U.S. Centers for Disease Control and Prevention (CDC) reported that wastewater activity for COVID-19 has climbed to a “moderate” level nationwide, up from “low” the week before.

Age and hematologic disease length are positive predictors for CKD; acute lymphoblastic leukemia is a negative predictive factor.

The FDA has approved an expanded indication of the IV formulation of Avtozma to include the treatment of CRS in patients 2 years of age and older.

Patients who regularly use antiemetic medication, such as for nausea from chemotherapy, appear at increased risk for chronic kidney disease. Patients who use antiemetics have an increased risk of ...

The Food and Drug Administration (FDA) has approved the first generic version of Venofer ® (iron sucrose) Injection.

Research links environmental exposures to CKD development and progression. Here’s what clinicians and patients need to know.

The ArteraAI Prostate Test is intended to assist clinicians and patients with risk-based decisions in localized prostate cancer.

This is the first randomized trial to investigate metastasis-directed therapy plus continuous androgen deprivation therapy for oligometastatic prostate cancer.

Community oncology practices in the US have been experiencing drug shortages that seriously impact cancer care delivery, a survey suggests.